(Q36832106)

English

Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions

scientific article published on May 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

1 reference

Europe PubMed Central

Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

1 reference

based on heuristic

inferred from title

author name string

Bonavida B

1

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

language of work or name

0 references

publication date

1 May 2007

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

26

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

25

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

3629-3636

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

https://scigraph.springernature.com/pub.10.1038/sj.onc.1210365

0 references

Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210365

21 January 2018

Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210365

21 January 2018

Association of 75/80-kDa phosphoproteins and the tyrosine kinases Lyn, Fyn, and Lck with the B cell molecule CD20. Evidence against involvement of the cytoplasmic regions of CD20

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210365

21 January 2018

CD20-mediated apoptosis: signalling through lipid rafts

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210365

21 January 2018

Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210365

21 January 2018

NF-kappaB signaling. Many roads lead to madrid.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210365

21 January 2018

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210365

21 January 2018

Nitric oxide inhibits the transcription repressor Yin-Yang 1 binding activity at the silencer region of the Fas promoter: a pivotal role for nitric oxide in the up-regulation of Fas gene expression in human tumor cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210365

21 January 2018

Missing pieces in the NF-kappaB puzzle

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210365

21 January 2018

Prolonging remission with rituximab maintenance therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210365

21 January 2018

Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210365

21 January 2018

Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210365

21 January 2018

Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210365

21 January 2018

Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210365

21 January 2018

Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210365

21 January 2018

Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210365

21 January 2018

An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210365

21 January 2018

Current treatment options in aggressive lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210365

21 January 2018

Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210365

21 January 2018

Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210365

21 January 2018

Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-kappa B activity: role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210365

21 January 2018

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210365

21 January 2018

Mechanism of suppression of the Raf/MEK/extracellular signal-regulated kinase pathway by the raf kinase inhibitor protein

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210365

21 January 2018

Raf kinase inhibitor protein interacts with NF-kappaB-inducing kinase and TAK1 and inhibits NF-kappaB activation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210365

21 January 2018

CD20 monoclonal antibodies down-regulate IgM at the surface of B cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210365

7 January 2021

based on heuristic

inferred from DOI database lookup

The biology of CD20 and its potential as a target for mAb therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210365

7 January 2021

based on heuristic

inferred from DOI database lookup

Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210365

7 January 2021

based on heuristic

inferred from DOI database lookup

CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210365

7 January 2021

based on heuristic

inferred from DOI database lookup

Loss of CD20 expression in relapsed lymphomas after rituximab therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210365

7 January 2021

based on heuristic

inferred from DOI database lookup

Chondrogenic differentiation of mesenchymal stem cells is inhibited after magnetic labeling with ferumoxides

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210365

7 January 2021

based on heuristic

inferred from DOI database lookup

Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210365

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210365

7 January 2021

based on heuristic

inferred from DOI database lookup

Predominant expression of the long isoform of Bcl-x (Bcl-xL) in human lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210365

7 January 2021

based on heuristic

inferred from DOI database lookup

Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210365

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.ONC.1210365

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

release_cpq36scjsraynb5rg2fo34flhe

1 reference

https://api.fatcat.wiki/v0/release/cpq36scjsraynb5rg2fo34flhe

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36832106&oldid=1843264674"